Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
5 evidence topics · 4 sources
Competitive antagonism of the bradykinin B2 receptor
Potency and selectivity in vitro, ex vivo, and in vivo
In vitro pharmacological profile of deucrictibant and its active metabolite
“The present study describes the in vitro pharmacological characteristics of PHA-022121 and its active metabolite, PHA-022484 (M2-D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In mammalian cell lines, PHA-022121 and PHA-022484 show high affinity for the recombinant human bradykinin B2 receptor with Ki values of 0.47 and 0.70 nM, respectively, and potent antagonism of the human bradykinin B2 receptor with Kb values of 0.15 and 0.26 nM, respectively (calcium mobilization assay).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“potency at rat, mouse, rabbit and dog bradykinin B2 receptors is at least 100-fold lower than the potency at the human receptor for both compounds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It is about 20-fold more potent than icatibant at the human bradykinin B2 receptor as assessed using recombinant or endogenously expressed receptors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote